ZNF668 Antibody

What is ZNF668 and what are its primary cellular functions?

ZNF668 is a nucleolar protein belonging to the kruppel C2H2-type zinc-finger protein family and contains 16 C2H2-type zinc fingers. It functions primarily as a tumor suppressor through multiple mechanisms:

• Physically interacts with and regulates p53 and its negative regulator MDM2

• Prevents MDM2-mediated p53 ubiquitination and degradation

• Regulates autoubiquitination of MDM2 and its ability to mediate p53 degradation

• Plays a critical role in DNA damage response (DDR) pathways

• Required for double-strand break (DSB) repair following ionizing radiation

• Suppresses invasion and migration of non-small cell lung cancer (NSCLC) cells by downregulating Snail and increasing E-cadherin and ZO-1 expression

ZNF668 is predominantly localized in the nucleus, with particularly strong signals in nucleolus-like nodular structures, though weak cytoplasmic expression has been observed in some cell lines .

How is ZNF668 expression altered in cancer tissues?

ZNF668 expression shows significant alterations in multiple cancer types:

In NSCLC specifically, immunohistochemical analysis demonstrated that ZNF668 protein expression was decreased in lung tumors (51/167, 30.5%) compared with adjacent normal lung tissues (43/62, 69.4%; P<0.001) . Statistical analysis revealed that ZNF668 expression was negatively associated with increased tumor-node-metastasis stage (P=0.019) and lymph node metastasis (P=0.002) .

What typical antibody applications are available for ZNF668 research?

ZNF668 antibodies are commercially available for multiple applications:

Most anti-ZNF668 antibodies are rabbit or mouse polyclonal antibodies purified through antigen affinity chromatography . These antibodies typically recognize epitopes within the full-length human ZNF668 protein and have been validated in multiple cell lines including A549, HepG2, and COLO 320 cells .

How does ZNF668 contribute to DNA damage response pathways?

ZNF668 plays multifaceted roles in DNA damage response:

• DSB Repair Regulation: ZNF668-knockdown cells display significantly impaired double-strand break repair efficiency as measured by neutral comet assay. Following IR treatment, ZNF668-deficient cells show longer comet tails and a higher amount of damaged cells compared to control cells, indicating compromised DSB repair .

• HR-Directed Repair: ZNF668 is critical for the upstream process of Tip60-mediated histone acetylation leading to chromatin relaxation that facilitates repair protein recruitment and homologous recombination (HR)-directed repair of DSBs caused by ionizing radiation .

• UV Damage Response: ZNF668 promotes RPA phosphorylation and recruitment to DNA damage foci in response to UV radiation .

• Cell Survival Impact: Cell survival assays reveal that ZNF668-knockdown cells are more sensitive to IR than control cells, demonstrating that ZNF668-deficient cells have increased vulnerability to DNA damage-induced cell death .

Importantly, ZNF668 function appears to be dispensable for both ATM/Chk2 and ATR/Chk1 signaling after IR or UV treatment, respectively, suggesting its role is specific to repair processes rather than damage sensing .

What mechanistic interplay exists between ZNF668 and the p53 pathway?

ZNF668 regulates p53 through multiple mechanisms:

• Physical Interaction: ZNF668 physically interacts with both p53 and MDM2 as demonstrated through immunoprecipitation/Western blotting analysis and in vitro GST-protein binding assays .

• Stability Regulation: Overexpression of ZNF668 significantly increases p53 protein level and stability without affecting p53 mRNA levels. Conversely, ZNF668 depletion decreases both basal p53 levels and stress-induced p53 levels .

• MDM2 Binding Domains: Mapping studies identified regions aa84-aa190 and aa268-aa367 as particularly important for the interaction between MDM2 and ZNF668; when these regions are deleted, the MDM2-ZNF668 interaction is abolished .

• Cancer-Derived Mutations: Cancer-derived ZNF668 mutants (R556Q and A66T) show reduced interaction with MDM2 compared to wild-type ZNF668, suggesting these mutations may compromise tumor suppression functions .

• Downstream Effects: Increased p53 levels resulting from ZNF668 overexpression lead to increased expression of p53's downstream target p21, demonstrating functional activation of the p53 pathway .

How does ZNF668 regulate epithelial-mesenchymal transition in cancer?

ZNF668's role in epithelial-mesenchymal transition (EMT) has been investigated in NSCLC:

• Migration and Invasion Suppression: Transwell and wound healing assays demonstrate that ZNF668 overexpression significantly decreases cell invasion and migration in A549 cells, whereas ZNF668 depletion enhances migration of HBE cells .

• EMT Marker Regulation: ZNF668 overexpression downregulates Snail (an EMT inducer) while increasing expression of epithelial markers E-cadherin and ZO-1. Conversely, ZNF668 depletion results in increased Snail expression and decreased E-cadherin and ZO-1 expression .

• Selective Pathway Regulation: Interestingly, ZNF668 manipulation does not alter expression of other EMT-associated proteins, including occludin, α-catenin, β-catenin, Slug, Vimentin, N-cadherin, and Fibronectin, suggesting a specific regulatory pathway .

This selective regulation distinguishes ZNF668 from other EMT regulators that affect multiple EMT markers simultaneously, suggesting it may target specific regulatory nodes in the EMT pathway.

What are the optimal protocols for detecting ZNF668 in different cellular compartments?

For accurate detection of ZNF668 in different cellular compartments, consider the following methodology:

• Nuclear vs. Cytoplasmic Detection:

  • ZNF668 is predominantly nuclear with strong nucleolar localization

  • For subcellular fractionation, use differential centrifugation protocols optimized for nucleolar proteins

  • Nuclear extraction buffers should contain DNase I to release DNA-bound proteins

• Immunofluorescence Protocol:

  • Fix cells with 4% paraformaldehyde (20 minutes at room temperature)

  • Permeabilize with 0.2% Triton X-100 (10 minutes)

  • Block with 5% BSA/PBS (1 hour)

  • Incubate with primary anti-ZNF668 antibody (1:100-1:500 dilution, overnight at 4°C)

  • Use nucleolar markers (e.g., nucleostemin or NPM) for colocalization studies

• Western Blot Analysis:

  • ZNF668 typically appears as a 70-80 kDa band

  • Use nuclear extraction protocols to enrich for ZNF668

  • Validate antibody specificity through siRNA knockdown and/or overexpression controls

Immunofluorescence analysis reveals specific nuclear staining for ZNF668 with strong signals in nucleolus-like nodular structures in both MCF7 and MDA-MB-468 cells, and this localization can be confirmed by ZNF668's colocalization with known nucleolar proteins like nucleostemin (NS) and NPM .

What controls are essential when validating ZNF668 antibodies?

Comprehensive validation of ZNF668 antibodies requires multiple control strategies:

• Specificity Controls:

  • siRNA knockdown: Transfect cells with ZNF668-specific siRNA and verify reduction in signal

  • Overexpression: Transfect cells with V5-tagged ZNF668 and confirm signal increase

  • Knockout models: When available, use ZNF668 knockout cells/tissues as negative controls

• Peptide Competition:

  • Pre-incubate antibody with excess immunizing peptide

  • Signal should be abolished if antibody is specific

• Cross-Reactivity Assessment:

  • Test antibody reactivity across multiple species (reported reactivity includes human and mouse)

  • Test in multiple cell types with varying ZNF668 expression levels

• Cell Line Controls:

  • Positive controls: MCF7, MDA-MB-468, A549, HepG2, COLO 320

  • For known mutations: EVSAT breast cancer cell line (contains ZNF668 nonsense mutation)

The specificity of ZNF668 staining can be confirmed by V5 antibody staining in cells with overexpression of V5-tagged ZNF668, and antibodies have been validated in multiple cell lines including MCF7, HMECs, and U2OS human osteosarcoma cells .

What are the recommended procedures for studying ZNF668's role in DNA repair mechanisms?

To investigate ZNF668's functions in DNA repair, researchers should consider these methodological approaches:

• HR Repair Efficiency Assessment:

  • Use the DR-GFP reporter system in U2OS cells to quantify HR repair

  • Implement ZNF668 knockdown or overexpression to assess functional impact

  • Measure GFP-positive cell percentage by flow cytometry

• DNA Damage Quantification:

  • Neutral comet assay for DSB assessment

    • Score at least 50 cells per condition

    • Compare tail moments at multiple timepoints post-damage (e.g., 15 min, 60 min)

  • γH2AX immunofluorescence for DSB foci quantification

    • Count foci number per nucleus over repair time course

• Repair Protein Recruitment Analysis:

  • Monitor RAD51 foci formation after IR treatment

  • Compare ZNF668-depleted vs. control cells

  • Assess kinetics of recruitment (early vs. late time points)

• Cell Survival Assays:

  • Clonogenic survival assay following IR exposure

  • Compare survival curves between control and ZNF668-manipulated cells

Research has shown that ZNF668 knockdown compromises DSB repair efficiency, as cells display longer comet tails and a significantly higher amount of damaged cells 60 minutes post-IR treatment, and ZNF668 depletion significantly reduces RAD51 foci formation after IR treatment .

How should researchers address discrepancies between ZNF668 antibody reactivity across different experimental systems?

When encountering inconsistent ZNF668 antibody reactivity, implement this systematic troubleshooting approach:

• Antibody Epitope Analysis:

  • Different antibodies target distinct epitopes that may be differentially accessible

  • Map the epitope regions of available antibodies

  • Consider using multiple antibodies targeting different regions

• Post-Translational Modifications:

  • ZNF668 may undergo tissue/condition-specific modifications affecting epitope recognition

  • Investigate phosphorylation, ubiquitination, or SUMOylation patterns

  • Use phosphatase treatment to determine if modifications affect antibody binding

• Splice Variant Consideration:

  • Verify which ZNF668 isoforms are expressed in your experimental system

  • Design isoform-specific primers for RT-PCR validation

  • Select antibodies that recognize conserved regions across relevant isoforms

• Protein-Protein Interactions:

  • ZNF668 interactions with MDM2, p53, and nucleolar proteins may mask antibody epitopes

  • Use protein extraction methods that disrupt protein complexes

  • Consider native vs. denaturing conditions in experimental design

When troubleshooting, remember that ZNF668 has been successfully detected in multiple cell lines with signals between 70-80kD, and antibody specificity can be verified through siRNA knockdown and overexpression controls .

How do researchers reconcile the dual roles of ZNF668 in different cancer types and experimental models?

Understanding ZNF668's context-dependent functions requires careful consideration of:

• Cellular Context Integration:

  • ZNF668 shows tumor suppressive functions in both breast cancer and NSCLC, but through different mechanisms:

    • In breast cancer: Primarily through p53 stabilization

    • In NSCLC: Through EMT regulation via Snail/E-cadherin/ZO-1

  • Consider p53 status of experimental models (wild-type vs. mutant)

  • Assess baseline expression of EMT regulators in your model system

• Experimental Design Considerations:

  • Acute vs. chronic ZNF668 manipulation may yield different phenotypes

  • Transient transfection vs. stable expression systems can affect outcomes

  • In vitro vs. in vivo models may reveal different aspects of ZNF668 function

• Analytical Framework:

  • Perform comprehensive pathway analysis beyond single targets

  • Employ transcriptomic or proteomic approaches to identify model-specific effects

  • Consider tumor microenvironment factors in in vivo models

• Mutation-Specific Effects:

  • Different ZNF668 mutations (e.g., R556Q vs. A66T) may have distinct functional impacts

  • Cancer-derived ZNF668 mutants show reduced interaction with MDM2

  • Evaluate mutation effects on protein-protein interactions and subcellular localization

Research has demonstrated that ZNF668 effectively suppresses breast cancer cell proliferation in vitro and tumorigenicity in vivo through p53-related mechanisms , while in NSCLC it suppresses invasion and migration through regulation of EMT markers , highlighting its context-dependent functions.

What are the critical controls needed when evaluating ZNF668's impact on p53 stability?

To rigorously assess ZNF668's effects on p53 stability, implement these experimental controls:

• Protein Synthesis Controls:

  • Include cycloheximide chase experiments to distinguish synthesis vs. degradation effects

  • Compare p53 half-life in ZNF668-manipulated vs. control cells

  • Monitor both p53 protein and mRNA levels simultaneously

• MDM2 Pathway Controls:

  • Include MDM2 inhibitors (e.g., Nutlin-3a) as positive controls for p53 stabilization

  • Assess MDM2 auto-ubiquitination in parallel with p53 ubiquitination

  • Monitor p53 ubiquitination status using ubiquitin immunoprecipitation

• Stress Response Controls:

  • Compare DNA damage-induced vs. basal p53 stabilization

  • Include time course analyses after damage induction

  • Test alternative p53-activating stresses (e.g., ribosomal stress, hypoxia)

• Cell-Type Specific Validation:

  • Test effects in multiple cell types with varying p53 status

  • Include p53-null cells as negative controls

  • Use cells with known MDM2 amplification to test pathway specificity

Research has shown that ZNF668 overexpression significantly increases p53 level and stability without affecting p53 mRNA levels, while ZNF668 depletion decreases both basal p53 levels and stress-induced p53 levels, and ZNF668 binds to MDM2 to prevent MDM2-mediated p53 ubiquitination and degradation .

What approaches should researchers use to investigate ZNF668's transcriptional regulatory functions?

To explore ZNF668's transcriptional regulatory roles, employ these methodological approaches:

• Chromatin Immunoprecipitation (ChIP):

  • Use validated anti-ZNF668 antibodies to identify genomic binding sites

  • Perform ChIP-seq for genome-wide binding profile

  • Include controls for nucleolar protein enrichment patterns

  • Validate binding sites with ChIP-qPCR

• Transcriptome Analysis:

  • Compare RNA-seq profiles before/after ZNF668 manipulation

  • Identify direct vs. indirect transcriptional effects through integration with ChIP data

  • Perform pathway enrichment analysis of differentially expressed genes

• Protein Complex Characterization:

  • Identify ZNF668 transcriptional complexes through co-immunoprecipitation

  • Perform mass spectrometry to identify novel interaction partners

  • Validate interactions through reciprocal immunoprecipitation

• Functional Validation:

  • Use luciferase reporter assays with identified target promoters

  • Perform site-directed mutagenesis of ZNF668 binding sites

  • Assess effects of cancer-derived ZNF668 mutations on transcriptional activity

As ZNF668 belongs to the kruppel C2H2-type zinc-finger protein family and contains 16 C2H2-type zinc fingers, it is likely to function as a transcription factor , though its specific transcriptional targets remain to be fully characterized.

How can researchers effectively model the impact of ZNF668 mutations identified in cancer genomics databases?

To functionally characterize cancer-associated ZNF668 mutations:

• Mutation Selection Criteria:

  • Prioritize recurrent mutations (e.g., R556Q and A66T in breast cancer)

  • Focus on mutations in functional domains (zinc finger regions or protein interaction domains)

  • Consider mutational clustering patterns across cancer types

• Functional Assay Selection:

  • Protein-protein interaction: Co-IP with known partners (MDM2, p53)

  • Subcellular localization: Immunofluorescence microscopy

  • DNA binding: Electrophoretic mobility shift assay (EMSA)

  • Transcriptional activity: Reporter assays

  • DNA repair function: HR assays and comet assays

• Model System Development:

  • Generate isogenic cell lines using CRISPR/Cas9 to introduce specific mutations

  • Create patient-derived xenografts from tumors with ZNF668 mutations

  • Develop conditional knock-in mouse models

• Mutation Impact Assessment:

  • Compare wild-type vs. mutant in transformation assays

  • Assess tumorigenicity in mouse models

  • Perform comprehensive phenotypic and molecular profiling

Research has shown that cancer-derived ZNF668 mutants (R556Q and A66T) show reduced interaction with MDM2 compared to wild-type ZNF668, suggesting these mutations may compromise tumor suppression functions .